Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
ARAF Drugs in Development Report Overview
Serine/threonine-protein kinase A-Raf is an enzyme involved in the transduction of mitogenic signals from the cell membrane to the nucleus. The Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) drugs in development research report provides comprehensive information on the therapeutics under development for ARAF. The report also analyzes the stage of development, mechanism of action (MoA), route of administration (RoA), molecule type, therapy area, and indication.
The pipeline report covers the descriptive pharmacological action and product description of ARAF. It includes the complete research and development history as well as the latest news and press releases. Additionally, the report provides an overview of key players involved in ARAF therapeutic development and features dormant and discontinued products.
Buy the Full Report to Know More about the ARAF Pipeline Products
| Key Therapy Areas | · Oncology
· Genetic Disorders |
| Key Indications | · Colorectal Cancer
· Melanoma · Solid Tumor · Blood Cancer · Craniopharyngioma |
| Key Mechanism of Action | · Serine/Threonine Protein Kinase A Raf Inhibitor |
| Key Route of Administration | · Oral |
| Key Molecule Type | · Small Molecule |
| Leading Companies | · Jazz Pharmaceuticals Plc
· Samjin Pharm Co Ltd · Takeda Pharmaceutical Co Ltd |
| Enquiry & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
ARAF Pipeline Products Segmentation by Therapy Areas
The key therapy areas associated with ARAF drugs in development include oncology and genetic disorders. Oncology had the highest share among ARAF drugs in development in 2022.
ARAF Pipeline Products Analysis by Therapy Areas, 2022 (%)
Buy the Full Report for More Therapy Area Insights into the ARAF Pipeline Products
ARAF Pipeline Products Segmentation by Indications
A few of the key indications for ARAF drug application include colorectal cancer, melanoma, solid tumor, blood cancer, and craniopharyngioma, among others. ARAF drugs had the highest number of products in development for colorectal cancer, melanoma, and solid tumor in 2022.
ARAF Pipeline Products Analysis by Indications, 2022 (%)
Buy the Full Report for More Indication Insights into ARAF Pipeline Products
ARAF Pipeline Products Segmentation by MoA, RoA, and Molecule Types
The mechanism of action in ARAF drugs in development is Serine/Threonine Protein Kinase A Raf Inhibitor and the key molecule type is the small molecule. Oral RoA was the only way for ARAF drug administration in 2022.
Buy the Full Report for More MoA, RoA, and Molecule Type Insights into ARAF Pipeline Products
ARAF Pipeline Products - Competitive Landscape
Takeda Pharmaceutical Co Ltd had the highest number of products in the ARAF pipeline in 2022
A few of the leading companies associated with ARAF pipeline products are:
- Jazz Pharmaceuticals Plc
- Samjin Pharm Co Ltd
- Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd: Takeda Pharmaceutical is headquartered in Tokyo, Japan. It is a research-based pharmaceutical company that focuses on the discovery, development, manufacturing, marketing, commercialization, import, and export of pharmaceutical drugs. The company offers products in the areas of rare diseases, gastrointestinal, and oncology, among others. It markets products directly and through a network of wholesale distributors, retail chains, and other purchasing groups worldwide.
ARAF Pipeline Products Analysis by Companies, 2022 (%)
Buy the Full Report for More Company Insights into ARAF Pipeline Products
ARAF Pipeline Products - Featured News
11th November 2022: Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It announced two upcoming presentations at the Society for Neuro-Oncology (SNO) annual meeting that was held from November 16-20, 2022 in Tampa, Florida.
Buy the Full Report to Know More Featured News about ARAF Pipeline Products
Segments Covered in the Report
ARAF Pipeline Products Therapy Area Outlook (2022)
- Oncology
- Genetic Disorders
ARAF Pipeline Products Indication Outlook (2022)
- Colorectal Cancer
- Melanoma
- Solid Tumor
- Blood Cancer
- Craniopharyngioma
ARAF Pipeline Products MoA Outlook (2022)
- Serine/Threonine Protein Kinase A Raf Inhibitor
ARAF Pipeline Products RoA Outlook (2022)
- Oral
ARAF Pipeline Products Molecule Type Outlook (2022)
- Small molecule
Scope
The report provides:
- A snapshot of the global therapeutic landscape of Serine/Threonine Protein Kinase A Raf.
- Review of pipeline therapeutics for Serine/Threonine Protein Kinase A Raf by companies and universities/research institutes. The review is based on information derived from company and industry-specific sources.
- Information about pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Key companies involved in Serine/Threonine Protein Kinase A Raf therapeutics and enlist all their major and minor products.
- Evaluation of Serine/Threonine Protein Kinase A Raf therapeutics based on their mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline products.
- Reviews of the latest news related to pipeline therapeutics for Serine/Threonine Protein Kinase A Raf.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Serine/Threonine Protein Kinase A Raf.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies in the Serine/Threonine Protein Kinase A Raf market.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Serine/Threonine Protein Kinase A Raf pipeline depth and the focus on indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive products to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued products and applying this knowledge to pipeline development.
Table of Contents
Table
Figures
Frequently asked questions
-
Which was the leading therapy area in the ARAF drugs in development in 2022?
Oncology had the highest share among ARAF drugs in development in 2022.
-
Which was the leading indication for the ARAF drugs in development in 2022?
ARAF drugs had the highest number of products in development for colorectal cancer, melanoma, and solid tumor in 2022.
-
Which are the leading companies associated with ARAF drugs in development?
A few of the leading companies associated with the ARAF pipeline products are Jazz Pharmaceuticals Plc, Samjin Pharm Co Ltd, and Takeda Pharmaceutical Co Ltd, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Other Diseases reports